Keynote Speaker to Address Importance of University Technology Commercialization at Keiretsu Forum Investor Capital Expo in Philadelphia

It is as vital as ever to understand how to streamline the commercialization of technology being developed within universities and through university partnerships. At 7th Annual Keiretsu Forum Mid-Atlantic Investor Capital Expo, Keith Marmer, Executive Director, Associate Vice President for Technology & Venture Commercialization at the University of Utah, will explore this topic with attending investors.

Keiretsu Forum Mid-Atlantic Investor Capital Expo

Innovation is at the heart of many university's missions; they are developing cutting-edge advances in life sciences, technology, and more. It is as vital as ever to understand how to streamline the commercialization of technology being developed within universities and through university partnerships. At 7th Annual Keiretsu Forum Mid-Atlantic Investor Capital Expo, Keith Marmer, Executive Director, Associate Vice President for Technology & Venture Commercialization at the University of Utah, will explore this topic with attending investors.

In 1980 the U.S. Congress passed the Bayh-Dole Act. This legislation recognized that universities are closest to cutting-edge research and development; if they have proper incentives (i.e., financial return), commercialization will do more to benefit the public. Over the past 20 years, university commercialization has contributed to more than $1.3 trillion in U.S. gross industrial output, supported 4.3 million jobs, and led to the development of over 200 new drugs and vaccines.

Keith Marmer oversees an array of functions at the University of Utah, including invention analysis, patenting, licensing, starting new companies, providing seed grants, and other programs to support innovation and entrepreneurship. "Commercialization represents a form of distributing new knowledge in a tangible fashion," says Marmer. "For instance, universities often do not have the financial resources or expertise to bring a new therapeutic to market. The biopharmaceutical industry in almost all instances will only bring a therapeutic to market when they have patent protection. In this instance, the university typically does more good by protecting the intellectual property and licensing it rather than making it freely available."

Marmer will explore the balance of societal benefits, economic development, business partnerships, and entrepreneurial opportunity with investors attending this year's Expo to be held at the Union League of Philadelphia on Wednesday, Oct. 16. 

In addition to Keith Marmer's Keynote, the Investor Capital Expo will present twelve carefully screened early-stage entrepreneurs. Each presenting company has a completed due diligence report and investment package. Accredited angel investors and guests are welcome to attend. For more information and registration, visit http://keiretsuforum-midatlantic.com/investor-capital-expo

# # #

Since 2011 Keiretsu Forum Mid-Atlantic has been part of Keiretsu Forum, the world's largest and most active investment community of early-stage angel investors. Keiretsu Forum now includes 53 Chapters on four continents. The organization is renowned for its thorough due diligence and exceptional deal flow. For more information on becoming a member, topics related to the Keiretsu Forum Mid-Atlantic and South-East process, or to book Howard Lubert, Co-Founder for a keynote, panel or training opportunities, please contact info@KeiretsuForum.net

Source: Keiretsu Forum Mid-Atlantic


Categories: Venture Funding

Tags: Angel Investors, Exit, Life Science, Liquidity Event, MidAtlantic, Venture Funding


Additional Images

About AMS Communications

View Website

A boutique marketing firm that specializes in the tenacious art of weaving PR and social media into a channel which builds brand and business growth.

AMS Communications
5 Powell Court, Apt, Suite, Bldg. (optional)
Glen Mills, PA 19342
United States